Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia
BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that the European Medicines Agency (EMA) and the U.S. Food and Drug…